Passage Bio Inc (PASG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Passage Bio Inc (PASG) has a cash flow conversion efficiency ratio of -0.156x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.85 Million) by net assets ($31.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Passage Bio Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Passage Bio Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Passage Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Passage Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Passage Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
National Tyre & Wheel Limited
F:N37
|
0.148x |
|
INFLECTION RESOURCES LTD.
F:5VJ
|
-0.009x |
|
Zelan Bhd
KLSE:2283
|
-0.111x |
|
Fondia Oyj
HE:FONDIA
|
-0.113x |
|
Overactive Media Corp
V:OAM
|
0.033x |
|
PeterLabs Holdings Bhd
KLSE:0171
|
0.107x |
|
Aelis Farma SA
PA:AELIS
|
-0.635x |
|
Daesung Microbiological Labs. Co. Ltd
KQ:036480
|
0.027x |
Annual Cash Flow Conversion Efficiency for Passage Bio Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Passage Bio Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see PASG stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $61.26 Million | $-47.96 Million | -0.783x | -11.31% |
| 2023-12-31 | $111.28 Million | $-78.26 Million | -0.703x | -19.80% |
| 2022-12-31 | $201.37 Million | $-118.21 Million | -0.587x | -47.44% |
| 2021-12-31 | $318.66 Million | $-126.88 Million | -0.398x | -50.68% |
| 2020-12-31 | $304.71 Million | $-80.52 Million | -0.264x | -15.48% |
| 2019-12-31 | $174.35 Million | $-39.90 Million | -0.229x | -115.00% |
| 2018-12-31 | $-12.17 Million | $-18.57 Million | 1.525x | -- |
About Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galac… Read more